Latham & Watkins Advises Tyra Biosciences, Inc. on Upsized IPO

Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, has announced the pricing of its upsized initial public offering of 10,800,000 shares of common stock at an initial public offering price of US$16.00 per share. All of the shares are being offered by Tyra. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tyra, are expected to be US$172.8 million. The shares began trading on the Nasdaq Global Select Market on September 15, 2021 under the ticker symbol TYRA. The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, Tyra has granted the underwriters a 30-day option to purchase up to an additional 1,620,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents Tyra Biosciences in the offering with a corporate team led by San Diego partners Matt Bush and Cheston Larson, with associates Jeffrey Woodley and Rachel Staub. Advice was also provided on benefits & compensation matters by San Diego partner Holly Bauer, with Los Angeles associate Vanessa King.